Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity

Area of Science:

• Biochemistry
• Oncology
• Endocrinology

Background:

• Steroid 5α-reductase (SRD5A) activity is crucial for dihydrotestosterone (DHT) biosynthesis.
• SRD5A's role in human castration-resistant prostate cancer (CRPC) remains incompletely understood.
• DHT is a key androgen in prostate cancer development and progression.

Purpose of the Study:

• To investigate and characterize the activity of SRD5A in human CRPC cell lines.
• To analyze the biosynthesis of testosterone (T) and DHT in CRPC cells.
• To understand the relationship between SRD5A activity, DHT levels, and CRPC cell behavior.

Main Methods:

• Culturing two human CRPC cell lines (C4-2 and C4-2AT6).
• Utilizing ¹³C-[2,3,4]-androstenedione (13C-Adione) as a steroid precursor.
• Employing liquid chromatography/mass spectrometry (LC/MS/MS) to quantify ¹³C-[2,3,4]-testosterone (13C-T) and ¹³C-[2,3,4]-DHT (13C-DHT).

Main Results:

• The ratio of 13C-DHT to 13C-T, indicative of SRD5A activity, was significantly lower in C4-2AT6 cells compared to C4-2 cells.
• Elevated DHT concentrations demonstrated inhibitory effects on cell proliferation, not a proliferative effect.
• 5α-reductase inhibitors showed no inhibitory effect at clinically relevant concentrations.

Conclusions:

• CRPC cells may possess an intrinsic regulatory system to mitigate androgenic suppression.
• SRD5A activity is differentially regulated in CRPC cell lines.
• These findings suggest novel therapeutic targets beyond direct SRD5A inhibition for CRPC.